



**Asuragen, Inc.**  
2150 Woodward St. Austin, T.X. 78744  
PH: 512 681-5200  
T: 877.777.1874  
www.asuragen.com

## **Agendia Licenses RNARetain™ as Accessory to MammaPrint®**

**Agendia accesses Asuragen's proprietary pre-analytical solution for tissue preservation for use with Agendia's breast cancer profiling test.**

**Austin, Texas, USA and Amsterdam, The Netherlands – April 16, 2007** – Asuragen, Inc., an oncology molecular diagnostics company and molecular biology service provider, today announced it has granted a non-exclusive license to Agendia, B.V., a gene expression analysis-based diagnostics and clinical testing company. Under the terms of this agreement, Agendia has the right to use RNARetain™ globally for human diagnostic applications.

"We are very excited about having RNARetain used in conjunction with MammaPrint®. The tissue preservative solution has found widespread clinical application and is uniquely suited for preserving nucleic acid profiles in solid tissues, both normal and cancerous, for subsequent clinical testing," said Matt Winkler, CEO of Asuragen.

RNARetain, also known as *RNAlater*™ in the life sciences market, is a patented technology useful for stabilizing expression profiles, of both RNA and DNA, in tissues and cells.

"Access to RNARetain will provide Agendia with the opportunity to use a convenient shipping method. This allows us to offer our high quality analyses of tumor samples, like MammaPrint, around the globe", explained Dr. Bernhard Sixt, CEO of Agendia. Agendia's MammaPrint is a validated molecular-diagnostic test based on gene expression profiling of 70 genes that form a reliable predictor of the risk of cancer recurrence in individual breast cancer patients.

### **About Asuragen, Inc.**

Asuragen is a fully integrated diagnostics reagents company focused on molecular oncology and early detection of cancer, with emphasis on microRNA. Asuragen's current diagnostic product portfolio consists of Signature® Genetic Testing and Oncology Testing products, as well as industry leading controls and standards engineered using its patented Armored RNA® technology. Asuragen is empowered with not only a high level of scientific expertise, but also assay development, business infrastructure, GLP testing services and an established cGMP manufacturing facility that allow it to span the spectrum of discovery, testing, production and commercialization. Asuragen is dedicated to developing new technologies that will become cutting edge clinical products.

*RNAlater* is a trademark of Ambion, Inc.

For more information, visit [www.asuragen.com](http://www.asuragen.com).

### **About Agendia, B.V.**

Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test, MammaPrint, that predicts the risk of breast cancer recurrence. Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology

For more information, visit [www.agendia.com](http://www.agendia.com)

# # #

**Asuragen Contact:**

Cindy WalkerPeach, Ph.D.  
Corporate Development  
512 681-5200  
cwalkerpeach@asuragen.com

**US Media Contact:**

Ogilvy Public Relations Worldwide  
David Bashaw  
Phone: +1 (212) 880-5352  
david.bashaw@ogilvypr.com